NTLA vs VNRX

Intellia Therapeutics, Inc. vs VolitionRX Limited — Valuation Comparison 2026

NTLA

In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics, Inc.
Quality
6.5
out of 10
Value Trap
24
SAFE
Price
$14.07
Last close
Models
9/13
Active
VS

VNRX

In Vitro & In Vivo Diagnostic Substances
VolitionRX Limited
Quality
5.8
out of 10
Value Trap
18
SAFE
Price
$2.67
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType NTLA Fair ValueNTLA Upside VNRX Fair ValueVNRX Upside
Bayesian DCF Intrinsic $3.57 -74.7% $0.40 -85.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.55 -95.5% $3.22 +20.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $11.83 -15.9% $6.36 +138.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NTLA vs VNRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NTLA vs VNRX — Which Stock Is More Undervalued?

NTLA scores higher with a 6.5/10 quality rating vs VNRX's 5.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Intellia Therapeutics, Inc. (NTLA) and VolitionRX Limited (VNRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NTLA currently trades at $14.07 with a QOC of 6.5/10, while VNRX trades at $2.67 with a QOC of 5.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).